Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Single Quadrupole LC/MS

By Drug Discovery Trends Editor | March 3, 2010

Agilent Technologies Inc., has introduced the Agilent 6150B Series single quadrupole liquid chromatograph/mass spectrometer (LC/MS), a new generation of this workhorse instrument. The 6150B Series has substantially higher sample throughput and delivers unmatched performance in the single quad LC/MS category.

“Many users, such as drug discovery labs, are moving to faster chromatography,” said Wayne Duncan, Agilent single quadrupole LC/MS marketing manager. “This means that their mass specs must keep pace with very sharp, narrow chromatographic peaks lasting less than one second. The Agilent 6150B Series LC/MS is well-matched to the latest fast chromatography systems, enabling labs to run many more samples per day in a very robust way, without any loss of data quality.”

To match the speed of fast chromatography, including ultra highperformance liquid chromatography (UHPLC) such as the Agilent 1290 Infinity platform, the Agilent 6150B Series can scan at 10,000 amu per second, while maintaining exceptional data quality. This is important to confirm identification of the correct compound in the complex reaction mixtures such as those found in drug discovery synthesis.

The Agilent 6150B Series is the first Agilent single quadrupole LC/MS equipped with Agilent Jet Stream Technology, a unique sample inlet design that uses super-heated sheath gas to focus the ion stream entering the mass spec. The benefit is enhanced sensitivity from a stronger signal with lower relative standard deviation at the limit of detection. Agilent Jet Stream Technology has demonstrated the ability to provide efficient ionization for a broader range of compounds than electrospray
ionization or atmospheric pressure chemical ionization alone. This can also increase sample throughput by minimizing the need to rerun samples in multiple ionization modes to look for differences.

The Agilent 6150B Series joins two other single quad LC/MS models in the Agilent lineup: the 6120B, which is the easiest-to-use instrument for applications such as confirming identities of impurities in a QA/QC lab; and the 6130B, which is ideal for quantitative analysis of compounds over a broad range of molecular weight. Each Agilent 6100B Series model can be upgraded to higher levels of performance as needs change, protecting the lab’s investment.

Date: March 2, 2010
Source: Agilent Technologies Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE